New OHSU Research Uncovers Key Barrier, Further Advancing the Fight Against HIV

One of the challenges to curing HIV is that the disease lurks in the body, even when it’s being treated with anti-retroviral medication. Now this puzzle is one step closer to being solved. An ongoing study  by a team of researchers at Oregon Health & Science University’s Vaccine & Gene Therapy Institute (VGTI) has identified a key biological barrier to the goal of curing HIV infection in people on anti-retroviral therapy. This work, published in … Read More

Commercialization of an MRI breast cancer detection technology

In 2000, OHSU Advanced Imaging Research Center (AIRC) scientists developed the Shutter-Speed Model (“SSM”) for analysis of Dynamic-Contrast-Enhanced (“DCE-MRI”) data. Later, they realized SSM is not just another pharmacokinetic “model,” but actually a new paradigm (“SSP”). The SSP enables more accurate MRI measure of, among other parameters, Ktrans, the rate constant for contrast agent molecule movement between capillaries and extravascular tissue. The researchers determined that systematic errors in the standard tracer pharmacokinetic paradigm “SP” Ktrans … Read More

More from the Mello Lab: Buzzed birds slur their songs

Hot on the heels of their ground-breaking bird genome research, the Claudio Mello Lab and colleagues have published new work showing the effects of alcohol on bird vocalization. This PLOS ONE study, by Christopher Olson, Devin Owen, Andrey Ryabinin, and Claudio Mello, showed that alcohol causes the zebra finches to produce song that is quieter and less organized–in effect, it slurs and softens their songs. Interestingly, the alcohol did not affect other areas of their … Read More

OHSU’s Claudio Mello, Ph.D., and colleagues publish bird genomes

An international group of more than 200 scientists–including Oregon Health & Science University neuroscientist Claudio Mello, Ph.D.–has released the genome of common birds for the first time. This work illuminates the evolution of birds, including details about how they developed song. The consortium is publishing 23 papers across multiple journals this week, including 8 papers in a Dec. 12 special issue of Science. The 48 bird species studied include the crow, duck, and eagle, as … Read More

OHSU researcher Brian J. O’Roak, Ph.D., helps identify new genetic risk factors for autism

A study published online yesterday in Nature identifies genes that, if mutated, either result in autism or contribute to its risk. Brian J. O’Roak, Ph.D., first author on the study and assistant professor of molecular and medical genetics in the OHSU School of Medicine, worked on the study for the past three years in collaboration with scientists at three other institutions. The study looked at 2,500 families with autistic children and compared siblings with autistic … Read More

Vaccine & Gene Therapy Institute’s Jay Nelson awarded vaccine adjuvant discovery contract

Jay Nelson, director of the OHSU Vaccine & Gene Therapy Institute, has been awarded a $10 million contract from the National Institutes of Health for discovery work on new ways to improve vaccines. They were one of seven groups awarded such contracts. Vaccine adjuvants are compounds that bolster the innate immune response, essentially super-charging the vaccine. While adjuvants show great promise in improving vaccines and fighting disease, currently  just three are in use–scientists at VGTI … Read More

Orexigen featured in the Portland Business Journal

You may have read that a drug from an OHSU startup received FDA approval last month. In 2003, OHSU’s office of Technology Transfer & Business Development (TTBD) created a start-up company called Orexigen Therapeutics, Inc., with Michael Cowley, then a neuroscience researcher at the Oregon National Primate Research Center. Cowley’s work looks at the appetite-regulating pathways in the brain and how these pathways are affected by obesity. Orexigen Therapeutics became public in 2007, and now the … Read More

Collaboration in Collaborative Life Sciences Building yields hypertension breakthrough

David Ellison, M.D., professor of medicine at Oregon Health & Science University and staff physician at the Portland VA Medical Center, leads a group that has been studying causes of human hypertension. In a paper published September 24th in the Journal of Clinical Investigation, “Hyperkalemic hypertension-associated cullin 3 promotes WNK signaling by degrading KLHL3”, the group identified a novel and unexpected mechanism for this hypertensive disease.  This research was done in collaboration with groups in … Read More

OHSU startup Orexigen earns FDA approval

The office of Technology Transfer and Business Development is happy to announce that a drug from  Orexigen Therapeutics Inc., called Contrave, has been approved by the FDA. This drug helps with weight management, along with a reduced-calorie diet and increased physical activity, in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) who also have at least one weight-related comorbid condition. Contrave has two components: … Read More

TTBD Innovator Spotlight: Michael P. Hutchens, M.D., M.A.

The office of Technology Transfer & Business Development would like to highlight a particularly innovative or note worthy OHSU innovator and invention at the university. This Fall 2014 quarter, our office would like to congratulate Michael P. Hutchens, M.D., M.A., for his work on the “Disinfection device for medical access sites” and the “Anesthetic vapor delivery device” that he has created and submitted to our office. Dr. Michael Hutchens is an assistant professor in the … Read More

Welcome to the Research News Blog

Welcome to the Research News Blog

OHSU Research News is your portal to information about all things research at Oregon Health & Science University. Visit often for updates on events, discoveries, and important funding information.

Participation Guidelines

Remember: information you share here is public; it isn't medical advice. Need advice or treatment? Contact your healthcare provider directly. Read our Terms of Use and this disclaimer for details.